Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : Akro save search
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients
Published: 2022-02-08 (Crawled : 19:00) - biospace.com/
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.11%
H: 1.01%
C: 0.37%
phase 2 phase 2b therapeutics nash enroll
Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
treatment phase 2 nash phase 2b
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Published: 2021-07-08 (Crawled : 16:00) - akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: -0.46%
H: 3.63%
C: 0.25%
phase 2 hepatitis efruxifermin trial phase 2b
Akero Therapeutics Announces First Patient Randomized for Dosing in Phase 2b Study of Efruxifermin (EFX) in F2/F3 NASH Patients (HARMONY)
Published: 2021-03-23 (Crawled : 12:00) - ir.akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: -0.67%
H: 1.38%
C: -3.0%
phase 2 phase 2b nash efruxifermin
Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk At The Liver Meeting® 2020
Published: 2020-10-02 (Crawled : 15:25) - ir.akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: -1.34%
H: 1.95%
C: 0.69%
phase 2 liver efruxifermin nash phase 2b
Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy
Published: 2020-11-13 (Crawled : 15:25) - ir.akerotx.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 6.86%
H: 0.0%
C: -9.97%
phase 2 positive therapy efruxifermin nash potential phase 2b
Akero Therapeutics Initiates Phase 2b HARMONY Study of Efruxifermin (EFX) for the Treatment of NASH
Published: 2021-02-24 (Crawled : 15:00) - biospace.com/
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: -0.07%
H: 2.21%
C: 1.65%
treatment phase 2 nash phase 2b
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.